8-[[(9H-芴-9-基甲氧基)羰基]氨基]-1,4-二噁螺[4.5]癸烷-8-羧酸 | 369403-24-7

• 分子结构分类: 有机化合物 - 苯类化合物 - 芴
• 中文名称: 8-[[(9H-芴-9-基甲氧基)羰基]氨基]-1,4-二噁螺[4.5]癸烷-8-羧酸
• 中文别名: Fmoc-8-氨基-1,4-二氧杂螺环[4,5]癸烷-8-羧酸；8-(FMOC-氨基)-1,4-二氧杂螺[4.5]癸烷-8-甲酸
• 英文名称: 8-[[(9H-fluoren-9-ylmethoxy)carbonyl]amino]-1,4-dioxaspiro[4,5]decane-8-carboxylic acid
• 英文别名: N-Fmoc-amino-4-(ethylene ketal)cyclohexylcarboxylic acid；8-((((9H-Fluoren-9-yl)methoxy)carbonyl)amino)-1,4-dioxaspiro[4.5]decane-8-carboxylic acid；8-(9H-fluoren-9-ylmethoxycarbonylamino)-1,4-dioxaspiro[4.5]decane-8-carboxylic acid
• CAS: 369403-24-7
• 化学式: C₂₄H₂₅NO₆
• 分子量: 423.466
• InChiKey: JACJNSRYTDVVMR-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.2
• 重原子数：
  31
• 可旋转键数：
  5
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.42
• 拓扑面积：
  94.1
• 氢给体数：
  2
• 氢受体数：
  6

安全信息

• 海关编码：
  2932999099

反应信息

• 作为反应物：
  描述：

  8-[[(9H-芴-9-基甲氧基)羰基]氨基]-1,4-二噁螺[4.5]癸烷-8-羧酸 在 盐酸 作用下， 以 丙酮 为溶剂， 反应 4.0h， 以68.7 g的产率得到N-Fmoc-氨基-4-酮环己基羧酸
  参考文献：
  名称：

  固相合成取代的3-氨基-3'-羧基-四氢咔唑

  摘要：

  已经开发了两种相关的固相合成路线，其允许合成3-氨基-3'-羧基取代的四氢咔唑衍生物。可以在氨基和羧基官能团以及在四氢咔唑部分的氮和芳环上引入多样性。两种途径均依赖于Fmoc保护的1-氨基-4-氧代环己酮羧酸作为中心核心元素。羧基官能团的衍生可通过胺实现，氨基官能团的衍生可通过与卤代烷，异氰酸酯，活化的醇，磺酸氯或羧酸的反应来实现。四氢咔唑支架是通过费歇尔吲哚与苯基肼衍生物的环化反应生成的，从而在芳族部分引入了多样性。

  DOI：

  10.1016/j.tetlet.2004.12.058
• 作为产物：
  描述：

  9,12-dioxa-1,3-diazadispiro[4.2.4.2]tetradecane-2,4-dione 在 盐酸 、 乙醇 、 sodium hydroxide 作用下， 以 水 为溶剂， 生成 8-[[(9H-芴-9-基甲氧基)羰基]氨基]-1,4-二噁螺[4.5]癸烷-8-羧酸
  参考文献：
  名称：

  [EN] PEPTIDYL NITRILCOMPOUNDS AS PEPTIDASE INHIBITORS
  [FR] COMPOSÉS DE PEPTIDYLNITRILE À TITRE D'INHIBITEURS DE PEPTIDASES

  摘要：

  该发明涉及公式（II）化合物及其在治疗中作为肽酶抑制剂的用途。

  公开号：

  WO2012119941A1

文献信息

• Tetrahydrocarbazol derivatives as ligands for G-protein-coupled receptors (GPCR)
  申请人：ZENTARIS AG

  公开号：US20030232873A1

  公开（公告）日：2003-12-18

  This invention provides new tetrahydrocarbazole derivatives that act as ligands for G-protein-coupled receptors (GPCR), especially as antagonists of the gonadotropin-releasing hormone (GnRH). A pharmaceutical composition that contains these new tetrahydrocarbazole derivatives as well as a process for the production of the new tetrahydrocarbazole derivatives are also provided. Moreover, this invention relates to the administration of tetrahydrocarbazole derivatives for treating pathologic conditions that are mediated by GPCR, especially for inhibiting GnRH, in mammals, especially humans, who require such an administration, as well as the use of tetrahydrocarbazole derivatives for the production of a pharmaceutical agent for treating GPCR-mediated pathologic conditions, especially for inhibiting GnRH.

  这项发明提供了作为G蛋白偶联受体（GPCR）配体的新四氢咔唑衍生物，特别是作为促性腺激素释放激素（GnRH）的拮抗剂。还提供了一种含有这些新四氢咔唑衍生物的药物组合物，以及一种生产这些新四氢咔唑衍生物的方法。此外，这项发明涉及给哺乳动物，特别是人类，需要这种给药的通过四氢咔唑衍生物治疗GPCR介导的病理状况，特别是抑制GnRH的治疗，以及利用四氢咔唑衍生物生产用于治疗GPCR介导的病理状况，特别是抑制GnRH的药物的用途。
• Identification and optimization of novel partial agonists of Neuromedin B receptor using parallel synthesis
  作者：Stephen J. Shuttleworth、Mike E. Lizarzaburu、Anne Chai、Peter Coward

  DOI：10.1016/j.bmcl.2004.04.045

  日期：2004.6

  The design and parallel synthesis of potent, small molecule partial agonists of Neuromedin B receptor based on the 3-amino-2,3,4,9-tetrahydro-1H-carbazole-3-carboxylic acid amide core is described. (C) 2004 Elsevier Ltd. All rights reserved.
• SYNTHETIC APOLIPOPROTEINS, AND RELATED COMPOSITIONS METHODS AND SYSTEMS FOR NANOLIPOPROTEIN PARTICLES FORMATION
  申请人：LAWRENCE LIVERMORE NATIONAL SECURITY, LLC

  公开号：US20180186860A1

  公开（公告）日：2018-07-05

  Synthetic apolipoproteins based on native/naturally occurring homolog proteins can be prepared using solid-phase peptide synthesis approaches combined with native chemical ligation methods to create analogs of full length apolipoproteins. The chemical synthesis is expected to allow introduction of non-natural amino acids, e.g., α,α′-dialkyl amino acids, with a periodicity that encourages both helix formation and amphipathicity. Such apolipoprotein analogs are expected to encourage, in some embodiments, facile and more complete NLP formation, enabling consideration of full spectrum of nanoparticle-based biotechnology applications ranging from therapeutic sequestration and delivery to energy/biofuel production to biopolymer production.
• US7122570B2
  申请人：——

  公开号：US7122570B2

  公开（公告）日：2006-10-17
• [EN] SYNTHETIC APOLIPOPROTEINS, AND RELATED COMPOSITIONS METHODS AND SYSTEMS FOR NANOLIPOPROTEIN PARTICLES FORMATION<br/>[FR] APOLIPOPROTÉINES SYNTHÉTIQUE, ET COMPOSITIONS, PROCÉDÉS ET SYSTÈMES ASSOCIÉS POUR LA FORMATION DE PARTICULES DE NANOLIPOPROTÉINE
  申请人：L LIVERMORE NAT SECURITY LLC

  公开号：WO2017044899A1

  公开（公告）日：2017-03-16

  Synthetic apolipoproteins based on native/naturally occurring homolog proteins can be prepared using solid-phase peptide synthesis approaches combined with native chemical ligation methods to create analogs of full length apolipoproteins. The chemical synthesis is expected to allow introduction of non-natural amino acids, e.g., α,α'-dialkyl amino acids, with a periodicity that encourages both helix formation and amphipathicity. Such apolipoprotein analogs are expected to encourage, in some embodiments, facile and more complete NLP formation, enabling consideration of full spectrum of nanoparticle-based biotechnology applications ranging from therapeutic sequestration and delivery to energy/biofuel production to biopolymer production.